molab.ai
Latest round
- Seed
Last raised
- May 2022
Total raised
- Undisclosed
Investors
- 1
About molab.ai
ai GmbH is a biotechnology research company that uses artificial intelligence to create precision molecules used for drug discovery and research.ai GmbH from Picus Capital. The firm offers an end-to-end drug discovery platform, featuring in-silico design, an ADMET prediction engine, and a compound optimization suite that provides AI-based (artificial intelligence) actionable recommendations that reduce the hit-to-lead and lead optimization projects. The platform provides technology solutions to create molecular structures, enhancing their potency and selectivity, for applications such as in vivo ADME, toxicity, and physiochemical properties.
Who invested in molab.ai
1 investor across 1 round
See all investors in molab.ai
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
May 16, 2022
Amount
Undisclosed
Investors
Questions about molab.ai
Who invested in molab.ai?
molab.ai has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has molab.ai raised?
molab.ai has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did molab.ai last raise money?
molab.ai's most recent round on record is a Seed, in May 2022.
What does molab.ai do?
ai GmbH is a biotechnology research company that uses artificial intelligence to create precision molecules used for drug discovery and research.
Where is molab.ai headquartered?
molab.ai is headquartered in Munich, Germany.
Which VCs invest in companies like molab.ai?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at molab.ai's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like molab.ai? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.